Euromonitor International
- Item successfully added to cart!
  
  Your cart is empty
  
  View Cart Check Out

Country Report

Analgesics in

Analgesics in the Netherlands

Oct 2020

US$990

Add to cart Pay by invoice

New Report Guarantee

If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE!

Executive Summary

New Report Guarantee

If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE!

2020 IMPACT

Analgesics sees initial spike in sales in 2020, as consumers stockpiled due to COVID-19

Growth in analgesics is high in 2020, with recorded sales spikes during the first weeks of the COVID-19 crisis. The expectation is that, in 2021 there will be a strong decline in comparison but, compared to pre-COVID-19 levels, sales of analgesics moving forwards are likely to be higher than as the virus is expected to flare up again on a seasonal or timely basis.

Ibuprofen sales restricted by negative publicity, whilst acetaminophen and aspirin benefit

Growth in other systemic categories in Q1 varied, with negative press on ibuprofen limiting sales growth in Western Europe and Latin America, for example. Whilst ibuprofen is still seeing decent growth, it is more modest than acetaminophen or combination products – analgesics.

Consumers turn to known and trusted brands, helping GSK Consumer healthcare to maintain its lead

GSK Consumer Healthcare took the lead in analgesics in 2019 and has maintained its top place. Backed by global player GlaxoSmithKline Plc, GSK Consumer Healthcare holds the top two brands in analgesics in the Netherlands, namely Panadol and Voltaren.

Files are delivered directly into your account within a few minutes of purchase.

Samples

Analgesics Market Sample Report Analgesics Market Sample Data

Overview

Why buy this report?

Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.

Samples (FAQs about samples):

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Analgesics industry in Netherlands with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Analgesics industry in Netherlands, our research will save you time and money while empowering you to make informed, profitable decisions.

The Analgesics in Netherlands market research report includes:

Analysis of key supply-side and demand trends
Detailed segmentation of international and local products
Historic volumes and values, company and brand market shares
Five year forecasts of market trends and market growth
Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

What is the market size of Analgesics in Netherlands?
What are the major brands in Netherlands?
Are combination products with acetaminophen still popular?

Why buy this report?

Gain competitive intelligence about market leaders
Track key industry trends, opportunities and threats
Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Want to find out more about this report?

Request more information

Analgesics in the Netherlands - Category analysis

KEY DATA FINDINGS

2020 IMPACT

Analgesics sees initial spike in sales in 2020, as consumers stockpiled due to COVID-19

Ibuprofen sales restricted by negative publicity, whilst acetaminophen and aspirin benefit

Consumers turn to known and trusted brands, helping GSK Consumer healthcare to maintain its lead

RECOVERY AND OPPORTUNITIES

Popularity of acetaminophen set to continue, as consumers deem it a safer and more appropriate medicine due to COVID-19

Private label players to gain from reduced disposable incomes, with opportunities to build greater consumer trust

Targeted products for different needs will help players to gain a competitive advantage

CATEGORY DATA

Table 1 Sales of Analgesics by Category: Value 2015-2020
Table 2 Sales of Analgesics by Category: % Value Growth 2015-2020
Table 3 NBO Company Shares of Analgesics: % Value 2016-2020
Table 4 LBN Brand Shares of Analgesics: % Value 2017-2020
Table 5 Forecast Sales of Analgesics by Category: Value 2020-2025
Table 6 Forecast Sales of Analgesics by Category: % Value Growth 2020-2025

Consumer Health in the Netherlands - Industry Overview

EXECUTIVE SUMMARY

COVID-19 impact on consumer health

COVID-19 country impact

Company response

Retailing shift

What next for consumer health?

MARKET INDICATORS

Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2015-2020
Table 8 Life Expectancy at Birth 2015-2020

MARKET DATA

Table 9 Sales of Consumer Health by Category: Value 2015-2020
Table 10 Sales of Consumer Health by Category: % Value Growth 2015-2020
Table 11 NBO Company Shares of Consumer Health: % Value 2016-2020
Table 12 LBN Brand Shares of Consumer Health: % Value 2017-2020
Table 13 Penetration of Private Label in Consumer Health by Category: % Value 2015-2020
Table 14 Distribution of Consumer Health by Format: % Value 2015-2020
Table 15 Distribution of Consumer Health by Format and Category: % Value 2020
Table 16 Forecast Sales of Consumer Health by Category: Value 2020-2025
Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2020-2025

Megatrends

Country Report

Analgesics in the Netherlands

New Report Guarantee

Executive Summary

New Report Guarantee

2020 IMPACT

Analgesics sees initial spike in sales in 2020, as consumers stockpiled due to COVID-19

Ibuprofen sales restricted by negative publicity, whilst acetaminophen and aspirin benefit

Consumers turn to known and trusted brands, helping GSK Consumer healthcare to maintain its lead

Samples

Overview

Why buy this report?

Samples (FAQs about samples):

Want to find out more about this report?

Table of Contents

Analgesics in the Netherlands - Category analysis

KEY DATA FINDINGS

2020 IMPACT

Analgesics sees initial spike in sales in 2020, as consumers stockpiled due to COVID-19

Ibuprofen sales restricted by negative publicity, whilst acetaminophen and aspirin benefit

Consumers turn to known and trusted brands, helping GSK Consumer healthcare to maintain its lead

RECOVERY AND OPPORTUNITIES

Popularity of acetaminophen set to continue, as consumers deem it a safer and more appropriate medicine due to COVID-19

Private label players to gain from reduced disposable incomes, with opportunities to build greater consumer trust

Targeted products for different needs will help players to gain a competitive advantage

CATEGORY DATA

Consumer Health in the Netherlands - Industry Overview

EXECUTIVE SUMMARY

COVID-19 impact on consumer health

COVID-19 country impact

Company response

Retailing shift

What next for consumer health?

MARKET INDICATORS

MARKET DATA

APPENDIX

OTC registration and classification

Vitamins and dietary supplements registration and classification

Self-medication/self-care and preventive medicine

Switches

GLOBAL MACROECONOMIC ENVIRONMENT

GLOBAL INDUSTRY ENVIRONMENT

DISCLAIMER

DEFINITIONS

SOURCES

Why buy this report?

Want to find out more about this report?

Recently Viewed

Complete Catalogue

Country Reports

Strategy Reports

Recently Viewed

Complete Catalogue

Country Reports

Strategy Reports